MedPath

FDA Approves Axsome's Auvelity for Major Depressive Disorder Treatment

The FDA has approved Axsome Therapeutics' Auvelity, a novel oral NMDA receptor antagonist, for treating major depressive disorder in adults. This marks the first new mechanism of action for an oral depression treatment in nearly 60 years, offering rapid efficacy starting within a week. Auvelity's approval highlights the ongoing need for faster-acting antidepressants to address the risk of self-harm in severely affected patients.

FDA Clears Axsome's Auvelity for Major Depressive Disorder

The U.S. Food and Drug Administration (FDA) has granted approval to Axsome Therapeutics for its depression therapy, Auvelity (dextromethorphan/bupropion), designed to treat major depressive disorder (MDD) in adults. This approval comes after a year-long delay, setting the stage for a fourth-quarter launch this year.

A New Mechanism of Action

Auvelity represents a significant advancement in depression treatment as the first and only oral NMDA receptor antagonist approved for MDD. It introduces a new mechanism of action not seen in oral depression therapies for nearly six decades. The combination of dextromethorphan, an NMDA antagonist found in cough syrups, and bupropion, an established antidepressant, works by increasing dextromethorphan levels in the blood and extending its half-life.

Rapid-Acting Efficacy

Clinical trials, including the GEMINI phase 3 trial, have demonstrated Auvelity's rapid-acting efficacy, with improvements in depressive symptoms observed as early as one week after treatment initiation. This rapid onset is crucial for patients at increased risk of self-harm, addressing a critical gap in current treatment options that can take weeks to show effects.

Addressing Unmet Needs

The approval of Auvelity underscores the pressing need for faster-acting antidepressant therapies. Current treatments, such as tricyclic antidepressants and selective serotonin reuptake inhibitors, often require several weeks to alleviate symptoms, leaving severely affected patients vulnerable. Auvelity's broad indication for MDD and its rapid efficacy profile offer a promising new option for patients and clinicians alike.

Future Prospects

Axsome Therapeutics views Auvelity's approval as a milestone, with potential for additional product launches in the near future. The company is also developing AXS-07 for migraine treatment and AXS-12 for narcolepsy, alongside its rights to Jazz Pharma's Sunosi for excessive daytime sleepiness. Auvelity's success could herald a new era of innovative treatments for neurological and psychiatric disorders.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Panel Approves Sage's Novel Antidepressant for Postnatal Depression, Rejects Alkermes' Treatment

An FDA advisory committee has voted in favor of Sage's Zulresso (brexanolone) for the treatment of postnatal depression, marking a significant step towards its approval as the first specific drug for this condition. However, the same panel rejected Alkermes' ALKS 5461 for major depressive disorder, citing concerns over its benefit-risk profile and trial design.

Axsome's AXS-05 Shows Promise in Alzheimer's Agitation Trials, NDA Submission Planned for 2025

Axsome Therapeutics' AXS-05 demonstrated a statistically significant delay in agitation relapse in Alzheimer's patients in the ACCORD-2 Phase 3 trial.
The ADVANCE-2 trial did not meet its primary endpoint, but results numerically favored AXS-05, with a good safety profile across trials.

AXS-12 Demonstrates Long-Term Efficacy and Safety in Narcolepsy Phase 3 Trial

Axsome Therapeutics' AXS-12 (reboxetine) significantly reduced cataplexy attacks compared to placebo in the Phase 3 ENCORE trial, meeting its primary endpoint.
Long-term treatment with AXS-12 showed sustained improvements in cataplexy, excessive daytime sleepiness, and cognition in patients with narcolepsy.

FDA Approves Axatilamab for Chronic Graft-versus-Host Disease After Steroid Failure

The FDA has granted accelerated approval to axatilamab for chronic graft-versus-host disease (GVHD) in adult and pediatric patients after failure of first-line steroid treatment.
Clinical trials demonstrated axatilamab significantly reduced GVHD symptoms in up to 75% of patients who had not responded to initial steroid-based therapy.

Axsome Therapeutics Reports Strong Q3 Growth and Advances CNS Pipeline

Axsome Therapeutics reported an 81% year-over-year increase in total net product revenue, reaching $104.8 million in the third quarter of 2024.
Auvelity sales grew by 113% year-over-year, with approximately 144,000 prescriptions written in Q3 2024, prompting a second sales force expansion planned for Q1 2025.

Autobahn Therapeutics' ABX-002 Receives FDA Clearance for Bipolar Depression Trial

Autobahn Therapeutics received FDA clearance for its IND application for ABX-002, an adjunctive treatment for bipolar depression.
A Phase 2 trial will commence by the end of 2024 to evaluate ABX-002 in patients with bipolar I or bipolar II disorder.

UWM-Developed Drug, GL-Damonia, Enters FDA Phase 1 Trials for Depression and Alzheimer's

A drug developed at the Milwaukee Institute for Drug Discovery (MIDD), called GL-Damonia, has entered FDA Phase 1 clinical trials, marking a significant milestone.
GL-Damonia, a derivative of benzodiazepines, aims to treat depression and Alzheimer's disease by promoting neuron regrowth without the side effects of existing medications.

FDA Accepts Axsome's NDA Resubmission for AXS-07 in Acute Migraine Treatment

The FDA has accepted Axsome Therapeutics' NDA resubmission for AXS-07, a novel oral treatment for acute migraine, with a PDUFA date set for January 31, 2025.
AXS-07 combines MoSEIC meloxicam and rizatriptan to provide rapid and consistent migraine relief, potentially addressing the unmet needs of patients dissatisfied with current treatments.

4DMedical, TrivarX, and Artrya Advance with FDA Clearances and US Partnerships

4DMedical's CT LVAS receives FDA clearance, expanding functional lung imaging accessibility in the US after its Australian rollout.
TrivarX accelerates its Phase 2 study for Major Depressive Episode, aiming to validate its MEB-001 algorithm for screening and diagnosis.

FDA Approves Exxua (Gepirone ER), a Novel Selective 5-HT1A Receptor Agonist for Major Depressive Disorder

The FDA has approved Exxua (gepirone hydrochloride extended-release tablets) for treating major depressive disorder (MDD) in adults, marking a new class of antidepressant.
Exxua is the first and only approved antidepressant with a novel mechanism that selectively targets the serotonin 1A receptor, a key regulator of mood and emotion.

Reference News

[1]
Axsome bounces back as FDA clears depression drug
pharmaphorum.com · Apr 17, 2025

Axsome Therapeutics' Auvelity, an oral NMDA receptor antagonist for major depressive disorder, gains FDA approval, marki...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy